As we begin the first month of the year 2020, it’s time to take a look at the drug candidates lined up at the FDA altar awaiting the federal agency's decision.
Forty-eight *novel drugs and biologics received FDA approval in 2019 compared to an all-time high of 59 in 2018. The only other time when the approval tally was above 50 was in 1996 – with 53 approvals.
*Novel drugs are new molecular entities (NMEs) having chemical structures that have never been approved before.